Trials / Completed
CompletedNCT02127801
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
A Single Dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic Rhinitis Subjects Challenged Intranasally With Allergen Extract
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are to assess the efficacy, safety and tolerability of a single dose of REGN1908-1909 in allergic adult participants, to collect information about how much REGN1908-1909 is in blood over time and to collect information about how the body reacts to REGN1908-1909.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1908-1909 | |
| DRUG | placebo |
Timeline
- Start date
- 2014-10-31
- Primary completion
- 2015-12-31
- Completion
- 2015-12-31
- First posted
- 2014-05-01
- Last updated
- 2020-12-16
Locations
5 sites across 4 countries: Netherlands, New Zealand, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02127801. Inclusion in this directory is not an endorsement.